Neuroanatomy, Neurophysiology and Neurodevelopment · 6 min read
Dopamine Pathways, Serotonin Receptors and Receptor-Based Reasoning
This chapter links the four classic dopamine pathways and the main serotonin, adrenergic and other receptor subtypes to symptoms and drug effects. It is one of the highest-yield areas of the Scientific Foundation domain, because a single question can test the pathophysiology of psychosis, a side effect and a treatment choice at once.
The Four Dopamine Pathways
Dopamine neurons arise mainly in the ventral tegmental area (VTA), the substantia nigra and the hypothalamus. The classic dopamine hypothesis of schizophrenia holds that positive symptoms reflect excess dopamine in the mesolimbic pathway, while negative and cognitive symptoms reflect too little dopamine in the mesocortical pathway. Antipsychotics that block D2 receptors everywhere relieve mesolimbic excess but also block the nigrostriatal and tuberoinfundibular pathways, which explains extrapyramidal symptoms and hyperprolactinemia.
| Pathway | Route | Normal role | Effect of D2 blockade |
|---|---|---|---|
| Mesolimbic | VTA to nucleus accumbens and limbic areas | Reward, motivation, salience | Reduces hallucinations and delusions (therapeutic) |
| Mesocortical | VTA to prefrontal cortex | Cognition, motivation, affect | May worsen negative and cognitive symptoms |
| Nigrostriatal | Substantia nigra to striatum (caudate, putamen) | Motor control | EPS: dystonia, akathisia, parkinsonism; tardive dyskinesia with long exposure |
| Tuberoinfundibular | Hypothalamus to anterior pituitary | Dopamine inhibits prolactin release | Hyperprolactinemia: galactorrhea, amenorrhea, sexual dysfunction, bone loss |
D2 Occupancy Thresholds
PET studies show a therapeutic window for D2 occupancy. Antipsychotic response generally requires about 60-65% striatal D2 occupancy; the risk of hyperprolactinemia rises above roughly 72%, and EPS become likely above about 78-80%. This is why higher doses of a first-generation antipsychotic add side effects without proportionally more benefit, and why the principle of the lowest effective dose matters. Clozapine and quetiapine produce antipsychotic effects at lower and more transient D2 occupancy, which explains their very low EPS and prolactin liability.
Why Second-Generation Antipsychotics Cause Fewer EPS
Second-generation antipsychotics combine D2 antagonism with stronger 5-HT2A antagonism. Serotonin acting at 5-HT2A receptors normally inhibits dopamine release in the nigrostriatal and mesocortical pathways; blocking 5-HT2A releases that brake, restoring some dopamine where it is needed for movement and cognition. Some agents also dissociate quickly from D2 receptors. Partial agonists (aripiprazole, brexpiprazole, cariprazine) work differently: they act as functional antagonists where dopamine is high and as agonists where it is low, stabilizing dopamine tone. Their characteristic adverse effect is akathisia rather than prolactin elevation; aripiprazole often lowers prolactin.
Pimavanserin, used for Parkinson disease psychosis, is a 5-HT2A inverse agonist with no meaningful D2 blockade, so it does not worsen motor symptoms. Xanomeline-trospium treats schizophrenia through muscarinic M1/M4 agonism, indirectly reducing striatal dopamine release without blocking D2 receptors, so EPS and prolactin elevation are not expected.
Serotonin Receptor Subtypes
Serotonin acts at at least 14 receptor subtypes, and boards test a handful. The 5-HT1A receptor is both a somatodendritic autoreceptor on raphe neurons and a postsynaptic receptor; buspirone and vilazodone are 5-HT1A partial agonists. When an SSRI first raises synaptic serotonin, 5-HT1A autoreceptors initially slow raphe firing; over two to several weeks these autoreceptors desensitize, firing recovers and serotonin output rises, one explanation for the delayed onset of antidepressant action. The 5-HT2A receptor is the target of psychedelics (agonism) and of SGAs, mirtazapine, trazodone and pimavanserin (antagonism or inverse agonism). 5-HT2C blockade contributes to appetite and weight gain (olanzapine, mirtazapine), while 5-HT2C stimulation early in SSRI treatment may contribute to jitteriness. 5-HT3 receptors in the gut and the brainstem chemoreceptor trigger zone mediate nausea; mirtazapine and vortioxetine block them, which is why they cause less nausea than SSRIs.
| Receptor | Effect of stimulation | Drugs acting here |
|---|---|---|
| 5-HT1A | Anxiolysis, antidepressant effect; autoreceptor brake on firing | Buspirone, vilazodone, aripiprazole (partial agonists) |
| 5-HT2A | Hallucinogenic effects, inhibits dopamine release | SGAs, mirtazapine, trazodone, pimavanserin (block) |
| 5-HT2C | Appetite suppression, early activation | Olanzapine, mirtazapine, quetiapine (block: weight gain) |
| 5-HT3 | Nausea, vomiting, GI motility | Mirtazapine, vortioxetine, ondansetron (block) |
Adrenergic and Other Receptors
Alpha-1 receptors on vascular smooth muscle maintain blood pressure on standing; blockade by low-potency FGAs, quetiapine, clozapine, iloperidone, trazodone, TCAs and prazosin causes orthostatic hypotension, dizziness and falls. Alpha-1 blockade by trazodone also contributes to priapism. Presynaptic alpha-2 receptors inhibit norepinephrine release: clonidine and guanfacine stimulate them, reducing sympathetic outflow (ADHD, hyperarousal, opioid withdrawal symptoms, Tourette tics), while mirtazapine blocks them, increasing serotonin and norepinephrine release. Beta-adrenergic blockade by propranolol treats lithium tremor, akathisia and the somatic symptoms of performance anxiety. At the mu opioid receptor, methadone is a full agonist, buprenorphine a high-affinity partial agonist, and naltrexone and naloxone antagonists; at nicotinic alpha-4-beta-2 receptors, varenicline is a partial agonist.
| Receptor blocked | Adverse effects | High-liability examples |
|---|---|---|
| D2 (nigrostriatal) | EPS, tardive dyskinesia | Haloperidol, fluphenazine, high-dose risperidone |
| D2 (tuberoinfundibular) | Hyperprolactinemia | Risperidone, paliperidone, haloperidol |
| H1 | Sedation, weight gain | Olanzapine, clozapine, quetiapine, mirtazapine |
| Muscarinic M1 | Dry mouth, constipation, retention, confusion | Clozapine, chlorpromazine, TCAs, paroxetine, benztropine |
| Alpha-1 | Orthostasis, dizziness, priapism | Clozapine, quetiapine, iloperidone, trazodone, TCAs |
Key Takeaways
- Mesolimbic excess explains positive symptoms; mesocortical deficit explains negative and cognitive symptoms; nigrostriatal blockade causes EPS; tuberoinfundibular blockade raises prolactin.
- Antipsychotic effect needs about 60-65% D2 occupancy; prolactin rises above about 72% and EPS above about 78-80%.
- 5-HT2A antagonism plus D2 antagonism is the SGA signature; partial agonists stabilize dopamine and cause akathisia more than prolactin elevation.
- SSRI onset delay is partly explained by gradual 5-HT1A autoreceptor desensitization.
- Pimavanserin (5-HT2A inverse agonist) and xanomeline-trospium (muscarinic agonist) treat psychosis without direct D2 blockade.
Study coach
Ask about this chapter
Answers come only from “Dopamine Pathways, Serotonin Receptors and Receptor-Based Reasoning”. If the chapter doesn't cover it, the coach will say so.
Finished reading?
Lock it in with a quick Neuroanatomy, Neurophysiology and Neurodevelopment quiz.